What We Do
We are focused on creating precision radiopharmaceutical therapies (RPTs) that transform people’s lives. With an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, we are at the forefront of pioneering the application of the next wave in cancer treatment.
Our Pipeline
Our pipeline programs leverage an alpha-emitting isotope, actinium 225, or Ac225 which offers a precision approach to patient treatment.
